Published in Medical Device Law Weekly, February 27th, 2005
These data further reinforce previous findings that Pulmicort in low doses is well tolerated in long term treatment of asthma in both adults and children.
Patients enlisted in the START study, the largest ever controlled asthma trial involving more than 7,000 patients in 32 different countries, were aged from 5-66 years and randomized to receive either Pulmicort or placebo once daily in addition to their usual asthma therapy.
Pulmicort was taken viaTurbuhaler...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Device Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.